Study sheds light on how fatty liver disease turns into liver cancer
A research team with the Hefei Institutes of Physical Science (HFIPS), Chinese Academy of Sciences reported their discovery that a metabolic regulation mechanism may play a role in malignant transformation of non-alcoholic steatohepatitis to liver tumor.
The study team led by Yang Wulin spent more than two years on this work that was published in International Journal of Biological Sciences last month.
Fatty liver, just as its name, is a common disease in liver marked with an excessive accumulation of fat in its cells.
There were two categories of fatty liver disease, non-alcoholic fatty liver disease (NAFLD) is the one the team explored. Gradually taking the main portion of fatty liver disease, non-alcoholic fatty liver disease progresses stage by stage, among which non-alcoholic steatohepatitis, usually called NASH, is the key stage, since it may turn into liver cancer.
The team was curious about the turning. They were planning to conduct a study to reveal the mechanism of how non-alcoholic steatohepatitis progresses to liver cancer.
Their work began with a mouse model that mimics the development of human fatty liver disease by studying changes in gene expression information that occur at various stages in the progression of NAFLD.
In each stage of the disease, they conducted deeper analysis on gene differential expressions and gene set variations. Then they found carcinogenic signals were extensively activated during NASH. Even more, there was fatty acid metabolism which was regulated by LPL/FABP4/CPT1 signal axis was specifically up-regulated. The two may work together to promote tumor-initiating cell formation and then malignant transformation begins..
Based on these analyses, the team conducted further laboratory studies, which showed that inhibition of LPL/FABP4/CPT1 signaling axis effectively inhibited liver tumor growth in vivo.
In addition, in vitro cell experiments also confirmed that targeted inhibition of the metabolic axis significantly reduced the self-renewal and proliferation capacity of liver cancer stem cells.
The team believes that inhibition of fatty acid metabolic signaling axis may prevent NAFLD from transforming into liver cancer, shedding new light on prevention of NASH-related liver cancer.
More information: Haoran Yang et al, Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer, International Journal of Biological Sciences (2021). DOI: 10.7150/ijbs.64714